You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies

 

Online download statistics by month:

Online download statistics by month: November 2020 to September 2024

AbstractFullPdf
Nov 2020128012
Dec 20202406
Jan 20211201
Feb 20212206
Mar 20213805
Apr 20212004
May 2021806
Jun 2021005
Jul 2021007
Aug 2021007
Sep 2021002
Oct 202116017
Nov 20218013
Dec 20212207
Jan 20221601
Feb 20221602
Mar 20221403
Apr 20223203
May 20223202
Jun 20223002
Jul 20222403
Aug 20221604
Sep 20223207
Oct 20221800
Nov 20221403
Dec 20223201
Jan 20231000
Feb 20231200
Mar 20231603
Apr 2023406
May 20231600
Jun 2023400
Jul 20232605
Aug 2023801
Sep 2023800
Oct 20231203
Nov 20231602
Dec 20231800
Jan 2024600
Feb 20241800
Mar 20241602
Apr 20241400
May 20241601
Jun 20245000
Jul 20248607
Aug 20242200
Sep 20242201
Total9740160